KBC Group
AXSM icon

KBC Group’s Axsome Therapeutics AXSM Stock Holding History

KBC Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$530K Buy
2,167
+1,046
+93% +$227K ﹤0.01% 792
2026
Q1 		$189K Hold
1,121
– – ﹤0.01% 986
2025
Q4 		$205K Hold
1,121
– – ﹤0.01% 909
2025
Q3 		$136K Hold
1,121
– – ﹤0.01% 1089
2025
Q2 		$117K Sell
1,121
-299
-21% -$31.7K ﹤0.01% 1101
2025
Q1 		$166K Buy
1,420
+84
+6% +$9.57K ﹤0.01% 1171
2024
Q4 		$113K Buy
1,336
+385
+40% +$35.4K ﹤0.01% 1472
2024
Q3 		$85K Hold
951
– – ﹤0.01% 1389
2024
Q2 		$77K Hold
951
– – ﹤0.01% 1330
2024
Q1 		$76K Buy
951
+264
+38% +$22.2K ﹤0.01% 1276
2023
Q4 		$55K Sell
687
-109
-14% -$7.29K ﹤0.01% 1451
2023
Q3 		$56K Buy
+796
New +$59.5K ﹤0.01% 1345

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

KBC Group's AXSM Position: Q2 2026 in Review

KBC Group increased its Axsome Therapeutics (AXSM) stake by 93% in Q2 2026, buying an estimated $227K and bringing the position to 2,167 shares worth $530K. The position accounts for ﹤0.01% of the portfolio, ranked #792.

KBC Group first reported a position in AXSM in Q3 2023 and has held it in 12 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • KBC Group held 2,167 shares of Axsome Therapeutics worth $530K as of Q2 2026.
  • KBC Group bought 1,046 Axsome Therapeutics shares in Q2 2026, an estimated $227K.
  • Axsome Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #792 holding.
  • KBC Group first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.